Dongming Zhang

Beijing, 100730, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 15 publications

Sensitivity of different epidermal growth factor receptor (EGFR) exon 19 deletion subtypes to first-line osimertinib in Chinese non-small cell lung cancer patients.

Sensitivity of different epidermal growth factor receptor (EGFR) exon 19 deletion subtypes to first-line osimertinib in Chinese non-small cell lung cancer patients.

Journal: BMC cancer

Published: November 13, 2025

Alectinib versus crizotinib as the first-line treatment in patients with advanced ALK-positive non-small cell lung cancer: a Chinese real-world cohort study.

Alectinib versus crizotinib as the first-line treatment in patients with advanced ALK-positive non-small cell lung cancer: a Chinese real-world cohort study.

Journal: Translational lung cancer research

Published: September 30, 2025

Prognostic Role of Early Dynamic Changes in Neutrophil-to-Lymphocyte Ratio of Nonsmall Cell Lung Cancer Patients.

Prognostic Role of Early Dynamic Changes in Neutrophil-to-Lymphocyte Ratio of Nonsmall Cell Lung Cancer Patients.

Journal: Journal of immunotherapy (Hagerstown, Md. : 1997)

Published: January 21, 2025

Lower respiratory tract microbiome is associated with checkpoint inhibitor pneumonitis in lung cancer patients.

Lower respiratory tract microbiome is associated with checkpoint inhibitor pneumonitis in lung cancer patients.

Journal: Translational lung cancer research

Published: September 19, 2024

Programmed death-ligand 1 tumor proportion score in predicting the safety and efficacy of PD-1/PD-L1 antibody-based therapy in patients with advanced non-small cell lung cancer: A retrospective, multicenter, observational study.

Programmed death-ligand 1 tumor proportion score in predicting the safety and efficacy of PD-1/PD-L1 antibody-based therapy in patients with advanced non-small cell lung cancer: A retrospective, multicenter, observational study.

Journal: Chinese medical journal

Published: June 13, 2024

Osimertinib versus comparator first-generation epidermal growth factor receptor tyrosine kinase inhibitors as first-line treatment in patients with advanced EGFR-mutated non-small cell lung cancer: a Chinese, multicenter, real-world cohort study.

Osimertinib versus comparator first-generation epidermal growth factor receptor tyrosine kinase inhibitors as first-line treatment in patients with advanced EGFR-mutated non-small cell lung cancer: a Chinese, multicenter, real-world cohort study.

Journal: Translational lung cancer research

Published: September 06, 2023

Clinical significance of DNA damage response mutations in stage I and stage IIIa NSCLC.

Clinical significance of DNA damage response mutations in stage I and stage IIIa NSCLC.

Journal: Thoracic cancer

Published: June 26, 2023

Blocking Adenosine/A2AR Pathway for Cancer Therapy

Blocking Adenosine/A2AR Pathway for Cancer Therapy

Journal: Zhongguo fei ai za zhi = Chinese journal of lung cancer

Published: July 28, 2022

Clinical characteristics and outcomes of immune checkpoint inhibitor-induced diabetes mellitus.

Clinical characteristics and outcomes of immune checkpoint inhibitor-induced diabetes mellitus.

Journal: Translational oncology

Published: May 17, 2022

Comparison of Chemotherapy Plus Pembrolizumab vs. Chemotherapy Alone in EGFR-Mutant Non-small-Cell Lung Cancer Patients.

Comparison of Chemotherapy Plus Pembrolizumab vs. Chemotherapy Alone in EGFR-Mutant Non-small-Cell Lung Cancer Patients.

Journal: Clinical lung cancer

Published: April 26, 2022

Safety and efficacy of immune checkpoint inhibitors in non-small cell lung cancer patients with preexisting antinuclear antibodies: a retrospective cohort study.

Safety and efficacy of immune checkpoint inhibitors in non-small cell lung cancer patients with preexisting antinuclear antibodies: a retrospective cohort study.

Journal: Translational lung cancer research

Published: April 14, 2022

Immune checkpoint inhibitor-related adverse events in lung cancer: Real-world incidence and management practices of 1905 patients in China.

Immune checkpoint inhibitor-related adverse events in lung cancer: Real-world incidence and management practices of 1905 patients in China.

Journal: Thoracic cancer

Published: November 22, 2021

Showing 1-12 of 15

Last Updated: 09/26/2026